Onderneming SENN AB Nasdaq Stockholm
Aandelen
SE0010219626
Biotechnologie & Medisch Onderzoek
Vakgebied
Verkoop per activiteit
SEK in miljoen | 2022 | Gewicht | 2023 | Gewicht | Delta |
---|---|---|---|---|---|
Genomic Allergen Rapid Detection
100,0
%
| 42 | 100,0 % | 50 | 100,0 % | +19,39% |
Verkoop per regio
SEK in miljoen | 2022 | Gewicht | 2023 | Gewicht | Delta |
---|---|---|---|---|---|
Sweden
100,0
%
| 42 | 100,0 % | 50 | 100,0 % | +19,39% |
Managers
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Peter Nählstedt
CEO | Chief Executive Officer | 50 | 01-01-18 |
Marianne Olsson
DFI | Director of Finance/CFO | 63 | 01-11-16 |
Henrik Johansson
CTO | Chief Tech/Sci/R&D Officer | 42 | 01-01-14 |
Director/Board Member | 59 | 15-10-14 | |
Public Communications Contact | 56 | 01-01-18 | |
Helen Olsson
HRO | Human Resources Officer | 59 | 01-01-20 |
Corporate Officer/Principal | 51 | 01-01-17 |
Besturend
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Founder | 76 | 18-08-10 | |
Director/Board Member | 59 | 15-10-14 | |
Paula Zeilon
BRD | Director/Board Member | 62 | 01-01-20 |
Director/Board Member | 65 | 01-01-20 | |
Peter Nählstedt
CEO | Chief Executive Officer | 50 | 01-01-18 |
Ian Kimber
BRD | Director/Board Member | 74 | 01-01-15 |
Aandelenklasse
Stemming | Aantal | Vrij verhandelbaar | Bedrijfseigen aandelen | Drijvend Totaal | |
---|---|---|---|---|---|
Aandeel A | 1 | 24 188 325 | 14 889 392 ( 61,56 %) | 0 | 61,56 % |
Bedrijfsgegevens
Sector
Vaira. 1 jan. | Kapi. | |
---|---|---|
-27,66% | 9,88 mld. | |
+26,94% | 2,89 mld. | |
-15,73% | 2,12 mld. | |
-20,83% | 1,67 mld. | |
+67,18% | 1,45 mld. | |
+26,08% | 788 mln. | |
-4,15% | 741 mln. | |
-28,78% | 514 mln. | |
+3,98% | 308 mln. |